The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 55.15%.However, over the last six months, we can see a weaker performance of 91.72%. Over the last 30 days, the price of LYEL has fallen by 28.09%. And in the last five days, it has surged by 44.02%.
Lyell Immunopharma Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $3.97 on 06/16/23 and the lowest value was $1.32 on 10/09/23.
52-week price history of LYEL Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Lyell Immunopharma Inc’s current trading price is -24.18% away from its 52-week high, while its distance from the 52-week low is 128.03%. The stock’s price range during this period has varied between$1.32 and $3.97. The Lyell Immunopharma Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.58 million for the day, a figure considerably higher than their average daily volume of 0.9 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Lyell Immunopharma Inc (LYEL) has experienced a quarterly rise of 36.82% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 764.84M and boasts a workforce of 224 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.09, with a change in price of +1.14. Similarly, Lyell Immunopharma Inc recorded 1,130,616 in trading volume during the last 100 days, posting a change of +60.96%.
LYEL’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LYEL stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.09.
LYEL Stock Stochastic Average
Lyell Immunopharma Inc’s raw stochastic average for the past 50 days is presently 84.31%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 89.66%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 88.33% and 82.10%, respectively.
